Comparison Of Efficacy Between Conbercept And Bromfenac As An Adjunctive Treatment With Conbercept For Age-related Macular Degeneration

OBJECTIVE:To investigate the clinical efficacy of bromfenac as an adjunctive treatment with Conbercept in the treatment of age-related macular degeneration(AMD).Select the June 2015 to October 2016 in 60 cases of age-related macular degeneration patients admitted to our hospital for the study,patients were monocular,a total of 60 eyes.Patients in the control group were treated with conbercept,and the patients in the trial group were treated with bromfenac as an adjunctive treatment with Conbercept.Both groups were given treatment for 3 months.The patients were followed up for 1,3 and 6 months after operation.The patients were performed a optical coherence tomography(OCT),fundus fluorescein angiography(FFA)and fundus indocyanine green angiography(ICGA)test.Finaly,the visual acuity,best corrected visual acuity,macular retina Thickness,the intraocular pressure,and the clinical efficacy and re-treatment of the two groups were evaluated and compared.Results:1.The results of visual changes:After 1 month operation,the improvement rate of visual acuity was 62.5%in the treatment group,which was higher than that in the control group(45.00%),but the difference was not significant(?2=3.986,P=0.056).After 3 months operation,the improvement rate of visual acuity was 80.0%in the treatment group,significantly higher than in the control group(55.00%)(?2=4.104,P=0.043).After 1 month operation,the best corrected visual acuity was 0.14±0.09 in the control group and 0.22±0.14 in the treatment group,which was significantly higher than that before the treatment(P<0.05),but the difference between the two groups was not significant.After 3 month operation,the best corrected visual acuity was 0.43 ± 0.12 in the treatment group,which was significantly higher than that in the control group(0.24±0.10,P<0.05).After 6 month operation,the The optimal visual acuity was 0.54±0.07 in the treatment group,which was significantly higher than that in the control group(0.37±0.16,P<0.05).2.The results of macular retinal thickness changes:Before operation,the control group and the treatment group with preoperative macular retinal thickness were 320.45±16.54?m and 318.74±17.68?m,respectively.Three follow-up after surgery,the thickness of macular retina in the control group decreased by 284.24 ±12.33?m,257.30±14.82?m and 240.74±19.32?m,respectively.Referral compared with the previous one,the retinal thickness decreased by 36.21±14.23?m,26.94±18.77?m,16.56(P<0.05).There was no significant difference between the two groups(P>0.05).The maximal retinal thickness of the treatment group was significantly decreased by 245.37±14.94?m,203.43±12.71?m and 184.14±18.75?m(P<0.05)).Referral compared with the previous one,decreased by 73.37±12.64?m,41.94±13.27?m,19.29±14.73?m,the first month after the decline in the first month,each time compared with the previous decline was statistically significant(P=(P<0.05).The rate of descending rate was 22.90%,35.98%and 42.00%in the treatment group,which was significantly higher than that in the control group(11.30%,19.71%,24.87%,P=0.040,P=0.025,P=0.030).3.The results of intraocular pressure.The intraocular pressure of the control group and the treatment group were 15.51 ±1.34 mmHg and 14.17 ± 0.86 mmHg,respectively.Three follow-up after surgery,the intraocular pressure was 14.48 ± 1.09 mmHg,14.23 ±1.10 mmHg and 13.57 ±1.16 mmHg in the control group,14.66 ±1.44 mmHg,13.45 ± 1.32 mmHg,13.94 ± 1.03 mmHg There was no significant difference between the two groups before and after treatment.There was no significant difference between the two groups in the same period.4.Adverse reactions.:In the control group,4 cases were subretinal fluid under OCT examination,1 case of retinal interstitial edema was found by OCT examination.In the treatment group,3 cases had retinal effusion by OCT examination.3 cases had retinal interstitial edema by OCT examination.Two patients had decreased visual acuity and one patient had visual deformity.All patients did not develop systemic adverse reactions after basic treatment,without neurological and psychiatric disorders.In conclusion:1.bromfenac as an adjunctive treatment with Conbercept for AMD patients with significant clinical efficacy,can significantly improve the patient's vision,so that patients get better corrected visual acuity,effectively reduce the patient's macular retina Thickness,and the treatment effect is better than Compaq.2.cbromfenac as an adjunctive treatment with Conbercept for AMD patients do not affect the patient's intraocular pressure,timely re-treatment,can be more effective to improve the treatment effect.3.bromfenac as an adjunctive treatment with Conbercept for AMD patients with high safety,worthy of clinical application.